Skip to main content
Top
Published in: Nutrition & Metabolism 1/2019

Open Access 01-12-2019 | Insulins | Research

Dietary chokeberry and dried jujube fruit attenuates high-fat and high-fructose diet-induced dyslipidemia and insulin resistance via activation of the IRS-1/PI3K/Akt pathway in C57BL/6 J mice

Authors: Oeuk Jeong, Hyun-Sook Kim

Published in: Nutrition & Metabolism | Issue 1/2019

Login to get access

Abstract

Background

The incidence of metabolic syndrome linked to dyslipidemia and insulin resistance has increased; thus, studies must be conducted to elucidate this phenomenon. The present study aimed to investigate the protective effects of chokeberry and dried jujube diet on high-fat and high-fructose diet-induced dyslipidemia in mice.

Methods

Male C57BL/6 J mice were divided into five groups: ND, mice fed normal diet and tap water; HFFD, mice fed 60% high-fat and 10% fructose diet (HFFD) in tap water; HFFD+C, mice fed HFFD with 1% chokeberry powder; HFFD+J, mice fed HFFD with 1% jujube fruit powder; and HFFD+M, mice fed HFFD with 0.5% chokeberry + 0.5% jujube fruit powder mixture.

Results

After 10 weeks of dietary treatment, chokeberry and dried jujube fruits reduced HFFD-induced weight gain and central obesity and decreased liver weight and abdominal and epididymal fat mass. Furthermore, such fruits attenuated HFFD-induced dyslipidemia; decreased triglyceride, total cholesterol, non-high-density lipoprotein-cholesterol, low-density lipoprotein-cholesterol, and very-low-density lipoprotein-cholesterol levels. Insulin resistance was improved via the consumption of dietary chokeberry and dried jujube fruits according to various indicators (serum insulin level, fasting blood glucose level, homeostatic model assessment-insulin resistance score, and oral glucose tolerance test value). These treatments were found to lower serum triglyceride levels. Moreover, the consumption of chokeberry and dried jujube changed the hepatic protein expression of insulin receptor, insulin receptor substrate 1, phosphoinositide 3-kinase, Akt, and catalase, which are associated with insulin resistance.

Conclusions

Chokeberry and dried jujube could be used in the management of dyslipidemia and insulin resistance associated with metabolic syndrome by reducing risk parameters in mice with HFFD.
Literature
16.
go back to reference Shao J, Yamashita H, Qiao L, Friedman JE. Decreased Akt kinase activity and insulin resistance in C57BL/KsJ-Leprdb/db mice. JEndocrinol. 2000;167(0022–0795 (Print)):107–115.CrossRef Shao J, Yamashita H, Qiao L, Friedman JE. Decreased Akt kinase activity and insulin resistance in C57BL/KsJ-Leprdb/db mice. JEndocrinol. 2000;167(0022–0795 (Print)):107–115.CrossRef
42.
go back to reference Zhuhua Z, Zhiquan W, Zhen Y, Yixin N, Weiwei Z, Xiaoyong L. A novel mice model of metabolic syndrome : the high-fat-high-fructose diet-fed ICR mice. Exp Anim. 2015;64(4):435–42.CrossRef Zhuhua Z, Zhiquan W, Zhen Y, Yixin N, Weiwei Z, Xiaoyong L. A novel mice model of metabolic syndrome : the high-fat-high-fructose diet-fed ICR mice. Exp Anim. 2015;64(4):435–42.CrossRef
51.
65.
go back to reference Góth L, Rass P, Páy A. Catalase enzyme mutations and their association with diseases. Mol Diagn 2004;8(3):141–149. doi:1084–8592. Góth L, Rass P, Páy A. Catalase enzyme mutations and their association with diseases. Mol Diagn 2004;8(3):141–149. doi:1084–8592.
67.
Metadata
Title
Dietary chokeberry and dried jujube fruit attenuates high-fat and high-fructose diet-induced dyslipidemia and insulin resistance via activation of the IRS-1/PI3K/Akt pathway in C57BL/6 J mice
Authors
Oeuk Jeong
Hyun-Sook Kim
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Nutrition & Metabolism / Issue 1/2019
Electronic ISSN: 1743-7075
DOI
https://doi.org/10.1186/s12986-019-0364-5

Other articles of this Issue 1/2019

Nutrition & Metabolism 1/2019 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine